ATYR Stock Analysis: Buy, Sell, or Hold?
ATYR - aTyr Pharma, Inc. Common Stock
$0.51
0.00 (0.75%)
▲
5d:
-16.2%
30d:
+6.84%
90d:
-37.33%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When ATYR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATYR is down 16.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATYR is down 16.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATYR is currently trading at $0.51, which is considered fair relative to its 30-day fair value range of $0.46 to $0.59.
Technical Outlook: Technically, ATYR is in a strong downtrend. The price is currently testing key support at $0.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.86 (+466.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATYR is in a strong downtrend. The price is currently testing key support at $0.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.86 (+466.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.46 -
$0.59
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 466.8% below Wall St target ($2.86)
- WARNING: Recommendation downgraded due to -16.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.46 -
$0.59
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.50
Resistance Level
$0.70
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.87
Wall Street Target
$2.86
(+466.8%)
Share & Embed Analysis
Last updated: July 14, 2026 10:41 AM ET
Data refreshes hourly during market hours. Next update: 11:41 AM
Data refreshes hourly during market hours. Next update: 11:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATYR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jill Marie Broadfoot
SELL
1558 shares
2026-02-04
Nancy Denyes
SELL
1118 shares
2026-02-04
Sanjay Shukla
SELL
3745 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
